Series
Radiotherapy
Status
Published
Date
Number of report
072
Selective internal radiation therapy
Ask the expert
The report presents a summary of reimbursement situation for selective internal radiation therapy in Europe.
The following indications will be considered:
- Primary liver cancer (hepatocellular carcinoma);
- Metastatic liver cancer.
Different types of microspheres for SIRT will be covered in the report, including those use the radionuclide yttrium-90 and based on the radionuclide holmium-166.
The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- France
- Germany
- Italy
- Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of treatment of selective internal radiation therapy (SIRT):
- Bio-Rad (Bio-Rex, Aminex)
- BTG (TheraSphere)
- Sirtex (Sir-spheres)
- Terumo (QuiremScout, QuiremSpheres)
Table of content is not available at the moment. Report is still ongoing.
24
Feb 2022
On January 18, 2022, the Ministry of Health has awarded the Framework Agreement for the acquisition of 81 linear accelerators included in the High-End Technology Equipment Investment Plan. Furthermore, the National Institute of Health Management (INGESA) has also initiated the processing of the Framework Agreement that will facilitate the acquisition of the equipment in the fields of interventional cardiology, interventional vascular radiology, interventional neurovascular, digital brachytherapy, computed tomography, magnetic resonance imaging, PET-CT, SPECT-CT.
Read more22
Feb 2022
In late January 2022, 19 new procedure codes were introduced by the Code Service of the Finnish National Health and Wellbeing Institution (THL). The introduced codes are dedicated to diagnostic imaging and image-guided interventions.
Read more18
Feb 2022
Dutch Organization for Health Research and Development, ZonMw awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program, including two projects for geriatric care, two projects for cancer, per one project for cardiovascular, neurovascular, and dermatology care.
Read more01
Nov 2021
The revised EBM (German Uniform Evaluation Standard) catalog came into force on October 1, 2021. The most significant changes concern mainly IVD tests: extension of the newborn screening, the introduction of microsatellite instability testing, amendments of Oncotype DX® test reimbursement, the introduction of screening for hepatitis B and C as part of health check-up, as well as changes in reimbursement of radiation therapy services.
Read more30
Sep 2021
At the beginning of September 2021, the Government of the Russian Federation released the preliminary version of the Program of State Guarantees for the period of 2022-2024. Major changes concerned the High-End Medical Care (HEMC) list I, where two new procedures in the cardiovascular and neurovascular field were added. The HEMC list II was expanded with the procedures in the field of radiotherapy, neurology, and neurosurgery, surgical procedures. The final version is expected at the beginning of 2022.
Read more